Get the Stockscreener App
14.06
1.33%
-0.19
After Hours:
14.06
Replimune Group Inc stock is traded at $14.06, with a volume of 478.09K.
It is down -1.33% in the last 24 hours and up +16.97% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
See More
Previous Close:
$14.25
Open:
$14.26
24h Volume:
478.09K
Relative Volume:
0.56
Market Cap:
$1.08B
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-4.4494
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
+3.23%
1M Performance:
+16.97%
6M Performance:
+43.76%
1Y Performance:
+83.79%
1-Day Range:
$13.86
$14.44
1-Week Range:
$13.33
$14.52
52-Week Range:
$4.92
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
14.06 | 1.08B | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Holdings of Replimune Group Inc (REPL) are aligned with the stars - SETE News
SG Americas Securities LLC Acquires 3,374 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Was there any good news for Replimune Group Inc (REPL) stock in the last session? - US Post News
Upward Trajectory: Replimune Group Inc (REPL) Posts a Slidee, Closing at 13.71 - The Dwinnex
Vanguard Group Inc's Strategic Acquisition of Replimune Group In - GuruFocus.com
Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Average Target Price from Analysts - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Consensus PT from Analysts - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Down 3.5%What's Next? - MarketBeat
What is Wedbush’s Estimate for Replimune Group Q3 Earnings? - Defense World
What is Wedbush's Estimate for Replimune Group Q3 Earnings? - MarketBeat
Replimune price target raised to $21 from $17 at H.C. Wainwright - Yahoo Finance
Replimune Group (NASDAQ:REPL) Shares Up 6% After Analyst Upgrade - Defense World
Replimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal year - MSN
Replimune announces priority review for its melanoma treatment - MSN
BMO Capital Markets Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock - MarketBeat
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA - Yahoo Finance
FDA accepts Replimune’s melanoma candidate for priority review - The Pharma Letter
Replimune Group (NASDAQ:REPL) Price Target Raised to $21.00 at HC Wainwright - MarketBeat
Replimune stock price target raised to $27 by BMO Capital - Investing.com Canada
Replimune stock soars on FDA priority review for melanoma treatment - MSN
Barclays maintains Replimune stock with $17 target By Investing.com - Investing.com Canada
FDA accepts Replimune's advanced melanoma therapy BLA - MSN
Replimune Stock Soars 16% on FDA Priority Review for Advanced Me - GuruFocus.com
Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy - Yahoo Finance
Replimune stock soars on FDA priority review for melanoma treatment By Investing.com - Investing.com Australia
Replimune Group (NASDAQ:REPL) Shares Gap UpHere's Why - MarketBeat
FDA accepts Replimune's advanced melanoma therapy BLA By Investing.com - Investing.com Australia
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma - The Manila Times
FDA Grants Priority Review to Replimune's Melanoma Treatment RP1, Breakthrough Therapy Status Secured - StockTitan
JPMorgan Chase & Co. Raises Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Trend Tracker for (REPL) - Stock Traders Daily
Replimune's SWOT analysis: biotech firm's stock poised for growth in oncology - MSN
Replimune Group (NASDAQ:REPL) Trading Down 6.6%Here's Why - MarketBeat
Barclays PLC Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Barclays PLC Has $1.74 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Replimune Awards Equity Incentives to 30 New Hires, Including 253,820 Shares in Options and RSUs - StockTitan
Replimune Group Inc (REPL-Q) QuotePress Release - The Globe and Mail
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials - The Manila Times
Replimune Launches Two Major Clinical Trials for Melanoma and Liver Cancer Treatment RP2 - StockTitan
Replimune Group, Inc. (NASDAQ:REPL) Receives $17.29 Consensus PT from Brokerages - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Up 9.5%What's Next? - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Increases Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):